|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lung Cancer | |||||
| Metastatic Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lung Neoplasms | |||||
| Neoplasm Metastasis | |||||
| 3 | More general conditions related to this trial | ||||
| Lung Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Neoplastic Processes | |||||
| Pathologic Processes | |||||
| Respiratory Tract Diseases | |||||
| Respiratory Tract Neoplasms | |||||
| Thoracic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| paclitaxel | |||||
| hyperthermia treatment | |||||
| isolated perfusion | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antimitotic Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Mitosis Modulators | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| Tubulin Modulators | |||||
| 6 | Sponsors listed in this trial | ||||
| NCI - Center for Cancer Research-Medical Oncology | |||||
| National Cancer Institute (NCI) | |||||